RE:Partnership deals are in vogueBeech, the post announcement part of the Endocyte / Merck story (re licensing of Phase III Vintafolide) is just as interesting. And, reflects very well for MCNA re future partnership deals / take over offers. ---- Bottomline, Vintafolide did not complete Phase III trial and the study was halted. Excerpt from article... "Merck and partner Endocyte have stopped a late-stage study of the ovarian cancer-treating vintafolide on the advice of a data safety monitoring board, saying the much-hyped drug failed to move the needle on progression-free survival. Reviewing vintafolide's Phase III results in an interim analysis, the board recommended that Merck halt its trial for futility, the company said." ¬--- https://www.fiercebiotech.com/story/merck-halts-study-billion-dollar-cancer-drug-vintafolide/2014-05-02 --- Back to MCNA, forget about a phase III interim results stage, MCNA is at the stage of filing for a BLA with the FDA. The market missed/has dismissed the importance of the following release from Bioniche / Telesta.... July 18-14 --- "Following several months of active dialogue with the U.S. Food and Drug Administration (FDA)....Bioniche has received written guidance.... permits the submission of an MCNA Biological License Application (BLA) for U.S. marketing approval review based on Bioniche's existing clinical trial data set. Dr. Michael Berendt, CEO of Bioniche Life Sciences Inc., commented: "This is the beginning of a new and significant transformative path for BCG refractory bladder cancer patients as well as for Bioniche and its shareholders." --- A significant/huge leap forward in potential value creation for the Telesta stock but not reflected in a sustainable share price increase. On a different note... Dear Glen Akselrod at Bristol Capital: PLEASE SHOW US WHAT YOU CAN DO asap. --- https://www.bristolir.com/ --- rg